Endocrine Abstracts

Objective: Some patients with Graves’ disease (GD) respond faster to antithyroid drugs (ATD) than others. Our aim was to study if levels of autoantibodies to the TSH-receptor (TRAb), thyroid-stimulating immunoglobulin (TSI), thyroid peroxidase antibodies (anti-TPO) and/or clinical factors influence the early response to anti thyroid drugs (ATD) in women with GD.Methods: This was a longitudinal cohort study of 65 women with GD and fT4 ≥50 pmol/...

Background: Graves’ disease (GD) is the most common form of hyperthyroidism in Sweden. About 2000 patients are affected by GD annually (incidence 21/100 000) and a majority are women in working age. GD can be overwhelming for the affected patient. Health care professionals do their best to meet the patients’ needs, but can we do more? The aim of this study was to explore patients’ experiences of being affected by GD to improve healthcare.M...

Background: Guidelines in healthcare shall be evidence-based, satisfy patients’ needs and improve patients’ outcomes. We aimed to estimate incremental costs after the introduction of a national guideline for Graves’ disease in Sweden adding the Graves’ Recurrent Events After Therapy (GREAT) score with genetic determinants to predict recurrence, a thyroid nurse, calcium-D-vitamin treatment preoperatively, and thyroid stimulating immunoglobulins.<p class=...

Background: Mental fatigue, depression and anxiety are common in Graves’ disease (GD). Our aims were to assess the relationship between these variables among GD patients both in the hyperthyroid phase and after treatment. The pathogenic mechanisms involved in these symptoms are unknown and so is if previous psychiatric disease influences these symptoms.Methods: This was a longitudinal case control study in Göteborg, Sweden, on 65 women with new...

Background: Graves orbitopathy (GO) is the most frequent and feared complication of Graves’ disease. In moderate-severe cases, intravenous (iv) glucocorticoids (GC) is the first-line treatment while Rituximab (RTX) is recommended as second-line treatment in patients non-responsive to GC. But data is scarce and contradictory.Objective: To investigate if patients with GO and poor response to iv GC benefit from a switch to RTX early in the treatment co...

Introduction: GH deficiency (GHD) in adults is associated with low serum levels of insulin-like growth factor 1 (IGF1) and a deteriorated cardio-metabolic profile. GH replacement therapy (GHRT) increases serum IGF1, an important mediator of the treatment response and safety marker of dose titration. The interindividual variation in treatment response is large and most likely influenced by genetic factors.Aim: The aim of this study was to test the hypothe...